Big3Bio provides recaps for events in the SFBay region, from major partnering/investor meetings to private forums and discussions. Check out all of the event recaps by Big3Bio correspondents here.
NOTE: Scroll through events via your browser’s SCROLL BAR on the right.
Speakers: S. Cyrus Khojasteh, PhD (Genentech), Bill Fitch, PhD (PosNeg Consulting), Shichang Miao, PhD (ChemoCentryx), Ryan Takahashi, PhD (Genentech), Raju Subramanian, PhD (Gilead), Shuguang Ma, PhD (Genentech) Organizers: Shuguang Ma, Shichang
Speakers: S. Cyrus Khojasteh, PhD (Genentech), Bill Fitch, PhD (PosNeg Consulting), Shichang Miao, PhD (ChemoCentryx), Ryan Takahashi, PhD (Genentech), Raju Subramanian, PhD (Gilead), Shuguang Ma, PhD (Genentech)
Organizers: Shuguang Ma, Shichang Miao
Registration fee (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0;
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Molecular Discovery; WuXi AppTec
Vendor show vendors registered to date: (14)Absorption Systems; Alturas Analytics; Bruker; CMIC, Inc.; Covance; Cytovier LLC; Intertek; MicroConstants; Pharmaron; PPD; Quotient Clinical Ltd; SCIEX; Seventh Wave; Zef Scientific
Registration deadline:2/22/2018 (it will close sooner if the seating cap is reached)
About the Topic
Metabolism plays a key role in the elimination of drugs and their pharmacokinetics. Identification of the metabolites is a major component in drug metabolism studies and is critical for both drug discovery and drug development. It requires careful strategic planning, utilization of modern analytical techniques in LCMS and NMR, and in-depth data analysis and interpretation. Deep understanding of the fundamentals of drug metabolism and organic chemistry is essential for a successful metabolite ID scientist. This workshop will discuss drug metabolizing enzymes, state-of-the-art techniques for generating, detecting, and identifying metabolites, data mining tools and MS/MS spectral interpretation, stage-based approaches for metabolite identification in drug discovery and development, and strategies for metabolites-in-safety testing.
This workshop will cover the following topics:
- Overview of drug metabolism and drug metabolizing enzymes
- Metabolite identification overview and metabolite detection techniques
- Metabolite structure identification by MS/MS and NMR
- General strategies for metabolite identification in drug discovery and development
- Metabolite generation techniques
- First-in-human metabolite profiling and metabolites-in-safety testing strategies
All Day (Thursday)
Crowne Plaza Hotel
San Francisco Airport - Burlingame
Genetic diseases affect 25 million Americans and countless more across the globe. Because genetic medicine is still in its adolescence, the space contains vast unmet needs and many grievous
Genetic diseases affect 25 million Americans and countless more across the globe. Because genetic medicine is still in its adolescence, the space contains vast unmet needs and many grievous conditions. These diseases are also often targetable via precision medicine ñ one can characterize the source of the disease, define the mechanism, and drug the molecular pathophysiology at its source.
BridgeBio Pharma is dedicated to finding and efficiently developing novel, genetically targeted therapies. Led by experienced scientists, drug developers and investors, BridgeBio combines deep research and development expertise with a corporate model that efficiently distributes central resources across multiple subsidiary companies, each of which develops a specific drug. The company has a portfolio of 17 targeted genetic drugs that run from preclinical to late-stage trials with the underlying premise that a more efficient drug development ecosystem is in patients’ best interests. These programs span multiple therapeutic areas including oncology, dermatology, mitochondrial disease, and cardiology. The fruits of this model are apparent in the work being done at subsidiary Eidos Therapeutics for patients with Transthyretin (TTR) Amyloidosis.
TTR Amyloidosis is a rare, devastating disease without an FDA-approved therapy which presents in two forms – a cardiomyopathy leading to progressive heart failure, and a polyneuropathy resulting in degeneration of sensory and motor function. Current treatment options for each focus upon symptom management and do not address the underlying source or mechanism of disease. TTR amyloidosis is brought on by the genetically-driven destabilization of a common blood borne tetramer (TTR), resulting in its disassociation into monomers, which then aggregate into amyloid fibrils and deposit in tissues where they cause disease. Eidos Therapeutics is developing a drug candidate, AG10, to treat this amyloidosis by stabilizing the TTR tetramer in the blood, halting the disease’s progression. AG10, conceived to mimic a saving mutation seen in nature that stabilizes TTR, has shown promising efficacy thus far, and will enter Phase II trials this spring.
(Wednesday) 6:00 pm - 8:00 pm
The Holiday Inn 275 S Airport Blvd South San Francisco
Interested in volunteering with WIB but aren’t sure how? Loved the events you’ve attended and would like to get more involved? Want to build your leadership skills? Looking to grow
Interested in volunteering with WIB but aren’t sure how? Loved the events you’ve attended and would like to get more involved? Want to build your leadership skills? Looking to grow your network? Come to our volunteer information session on February 28, 2018! You will learn all about what each of our volunteer committees do, what volunteering with us involves, and all the potential perks associated with volunteer work.
* – Walk-ins will be accepted at the door until event capacity is reached.
6:00 p.m. – 6:30 p.m. Check-in, Networking, and Refreshments
6:30 p.m. – 7:00 p.m. Committee descriptions from committee chairs
7:00 p.m. – 8:00 p.m. Network with committee chairs and other WIB members
(Wednesday) 6:00 pm - 8:00 pm